Novo Nordisk A/S
NVO58.740USD
-0.590-0.99%
Horário de mercado （ET）Cotações atrasadas em 15 min
197.60BValor de mercado
17.02P/L TTM
Mais detalhes de Novo Nordisk A/S Empresa
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Informações de Novo Nordisk A/S
Código da empresaNVO
Nome da EmpresaNovo Nordisk A/S
Data de listagemMay 17, 1974
CEODoustdar (Maziar Mike)
Número de funcionários76302
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 17
EndereçoNovo Alle 1
CidadeBAGSVAERD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísDenmark
Código postal2880
Telefone4544448888
Sitehttps://www.novonordisk.com/
Código da empresaNVO
Data de listagemMay 17, 1974
CEODoustdar (Maziar Mike)
Executivos da empresa Novo Nordisk A/S
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product & Portfolio Strategy
Executive Vice President - Product & Portfolio Strategy
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Chairman of the Board
Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Total GLP-1
5.75B
49.00%
Obesity (Wegovy®)
3.19B
27.15%
Long-acting insulin
657.86M
5.60%
Fast-acting insulin
643.61M
5.48%
Rare blood disorders
457.21M
3.89%
Outro
1.04B
8.88%
Por RegiãoUSD
Nome
Receita
Proporção
USA
6.44B
54.88%
Canada
2.63B
22.36%
Emerging Markets
1.04B
8.85%
APAC
856.16M
7.29%
Region China
777.53M
6.62%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Total GLP-1
5.75B
49.00%
Obesity (Wegovy®)
3.19B
27.15%
Long-acting insulin
657.86M
5.60%
Fast-acting insulin
643.61M
5.48%
Rare blood disorders
457.21M
3.89%
Outro
1.04B
8.88%
Distribuição de ações
Atualizado em: há 16 horas
Atualizado em: há 16 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
Outro
97.91%
Investidores
Investidores
Proporção
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
Outro
97.91%
Tipos de investidores
Investidores
Proporção
Investment Advisor
4.67%
Investment Advisor/Hedge Fund
2.42%
Research Firm
0.92%
Hedge Fund
0.38%
Pension Fund
0.33%
Bank and Trust
0.20%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
Outro
90.86%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
2822
305.86M
9.09%
-31.99M
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital International Investors
17.71M
0.53%
+6.09M
+52.42%
Sep 30, 2025
Loomis, Sayles & Company, L.P.
16.17M
0.48%
+3.59M
+28.54%
Sep 30, 2025
Putnam Investment Management, L.L.C.
13.64M
0.41%
+11.71M
+606.41%
Sep 30, 2025
Fidelity Management & Research Company LLC
12.61M
0.38%
-316.35K
-2.45%
Sep 30, 2025
Fisher Investments
10.32M
0.31%
-678.01K
-6.16%
Sep 30, 2025
Folketrygdfondet
10.21M
0.3%
+117.37K
+1.16%
Sep 30, 2025
Managed Account Advisors LLC
8.03M
0.24%
-775.24K
-8.80%
Sep 30, 2025
Fayez Sarofim & Co.
7.35M
0.22%
-3.15M
-29.99%
Sep 30, 2025
Everett Harris & Co.
6.39M
0.19%
-402.00
-0.01%
Sep 30, 2025
Parametric Portfolio Associates LLC
6.18M
0.18%
-49.63K
-0.80%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
Ver Mais
Roundhill GLP-1 & Weight Loss ETF
Proporção15.04%
VanEck Pharmaceutical ETF
Proporção14.55%
Amplify Weight Loss Drug & Treatment ETF
Proporção9.51%
The Opal International Dividend Income ETF
Proporção3.79%
TrueShares Low Volatility Equity Income ETF
Proporção3.21%
First Trust WCM International Equity ETF
Proporção2.68%
Invesco International Dividend Achievers ETF
Proporção1.8%
Putnam Focused Large Cap Value ETF
Proporção1.16%
SP Funds S&P World (ex-US) ETF
Proporção1.05%
ActivePassive International Equity ETF
Proporção0.95%
Dividendo
Um total de
18.01B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Final Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Ver Mais
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Aug 14, 2023
Split
1→2
Data
Data ex-dividendo
Tipo
Proporção
Aug 14, 2023
Split
1→2
